In the Claims:

Cancel Claims 1-10 and add new Claims 11-15 as follows:

11. A film-coated tablet comprising

a) a tablet core comprising a therapeutically effective dose of oxacarbazepine and excipients that are suitable for the production of granules, wherein said oxacarbazepine has a median particle size of approximately 2 to 12 μm, and a maximum residue on a 40 μm sieve of less than or equal to 5%; and

b) a hydrophilic permeable outer coating.

12. The film coated tablet according to Claim 11 wherein the oxacarbazepine has a median particle size of approximately 4 to 10 μm.

13. The film coated tablet according to Claim 12 wherein the oxacarbazepine has a median particle size of approximately 6 to 8 μm.

14. The film coated tablet according to Claim 11 wherein the oxacarbazepine has a maximum residue on a 40 μm sieve of less than or equal to 2%.

15. The film coated tablet according to Claim 11 wherein the hydrophilic permeable outer coating comprises white pigments, iron oxide pigment and optionally further excipients.

REMARKS

Claims 1-10 were originally filed in the application. By the present amendment, applicant has canceled Claims 1-10 and added new Claims 11-15 in order to remove indefinite language. Therefore, the claims remaining for consideration by the Examiner are Claims 11-15.

The Examiner noted that the above-identified application does not contain an abstract of the disclosure as required by 37 CRF 1.72(b).

In response, applicants' have provided an Abstract of the Disclosure on a separate sheet. Support for the abstract is found in canceled Claim 3 and in the specification as originally filed on page 6, lines 9-13.

In the Office Action mailed October 3, 2000, the Examiner stated that Claims 5 and 8 would be allowable if rewritten in independent form.